Petmed Express (PETS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$168.9M

Revenue (quarter)

$41.0M

Revenue growth (year over year)

−19.86%

Gross profit (trailing twelve months)

$47.1M

Gross margin

27.92%

Net income (trailing twelve months)

−$29.3M

Net income (quarter)

−$6.1M

Net income growth (year over year)

+82.01%

Net margin

−17.34%

Return on equity

−78.56%

EPS (trailing twelve months)

−$1.37

Book value per share

$1.06

P/E (trailing twelve months)

—

Price to book

1.15

Debt to assets

63.95%

Payout ratio

−170.18%

Dividend yield

—

Company profile

PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

• Is Petmed Express (PETS) profitable?

  No. Petmed Express reported a net loss of $29.3M over the trailing twelve months.

• How much revenue does Petmed Express (PETS) make?

  Petmed Express generated $168.9M in revenue over the trailing twelve months, down 19.86% year over year.

• How do I buy stock in Petmed Express (PETS)?

  PETS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.